Engelhard and colleagues investigated the immunogenicity of phospho-peptides from breast cancer antiestrogen resistance 3 (pBCAR3126–134) and insulin receptor substrate 2 (pIRS21097–1105) and concluded that the specific immunogenicity observed provides a rationale for immunotherapy targeting phospho-peptides [25]. This evidence concerns the gene IRS2 and breast carcinoma.